ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

130
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
Refresh
bullishLupin Ltd
10 May 2024 18:48Broker

Lupin - Niche Product Drives Earnings Growth

Motilal Oswal's research report onLupin Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended FY24 on a strong note, with...

Logo
322 Views
Share
bullishLupin Ltd
09 May 2024 21:51Broker

Lupin (LPC IN) - Margins to Sustain

Prabhudas Lilladher's research report onLupin We revise our FY25/26E EPS estimates by 2.1%/4.3%, as we factor in higher margins.

Logo
153 Views
Share
bullishLupin Ltd
09 May 2024 06:02Broker

LUPIN Ltd - Strong Gross Margins

Its revenue increased by 12%, supported by notable improvements in EBITDA margins, resulting in Reported PAT reaching Rs 561 Cr.

Logo
191 Views
Share
bullishLupin Ltd
24 Apr 2024 18:55Broker

Lupin Ltd - New Drugs Approvals Will Boost Future Prospects

The combined sales from these three drugs could potentially generate incremental sales of ~$100 Mn per year in the US market.

Logo
212 Views
Share
bullishLupin Ltd
18 Apr 2024 06:36Broker

Lupin Ltd - GSpiriva on a Healthy Growth Track, Headwinds Receding

This to result in $200-220 million sales on a quarterly basis. USFDA recently completed cGMP inspection of Dabhasa plant and zconcluded with no...

Logo
Sharekhan
175 Views
Share
x